Table 4 Variables associated with the combined clinical endpoint of RBV dose reduction, transfusion of erythrocyte concentrates, or administration of epoetin-α
| Â | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
Characteristics | Odds ratio [95% CI] | Pvalue | Odds ratio [95% CI] | Pvalue |
EPO rs1617640 (GG vs. TT/TG) | 4.19 [2.31 – 7.59] | < 0.001 | 4.14 [2.20 – 7.82] | < 0.001 |
Sex (female vs. male) | 0.45 [0.24 – 0.83] | 0.013 | 0.41 [0.21 – 0.80] | 0.003 |
Baseline Hb (g/dl) | 0.87 [0.70 – 1.09] | 0.24 | 0.83 [0.65 – 1.07] | 0.168 |
RBV start dose* | 1.21 [1.04 – 1.40] | 0.012 | 1.18 [1.01 – 1.39] | 0.036 |